Amedisys (NASDAQ:AMED – Get Rating) had its price target trimmed by Stephens from $155.00 to $125.00 in a research report released on Tuesday morning, The Fly reports. The firm currently has an equal weight rating on the health services provider’s stock.
A number of other research analysts have also weighed in on the company. UBS Group raised Amedisys from a sell rating to a neutral rating and boosted their target price for the stock from $152.00 to $168.00 in a report on Tuesday, March 1st. Deutsche Bank Aktiengesellschaft decreased their target price on Amedisys from $230.00 to $210.00 in a report on Friday, April 29th. Oppenheimer reaffirmed an outperform rating and issued a $200.00 price objective on shares of Amedisys in a report on Friday, April 29th. Benchmark decreased their price objective on Amedisys from $200.00 to $175.00 and set a buy rating on the stock in a report on Thursday, February 24th. Finally, BMO Capital Markets raised Amedisys from a market perform rating to an outperform rating and decreased their price objective for the company from $210.00 to $190.00 in a report on Friday, February 25th. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and ten have given a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of Moderate Buy and a consensus target price of $173.27.
Shares of Amedisys stock opened at $115.28 on Tuesday. The company has a quick ratio of 1.03, a current ratio of 1.03 and a debt-to-equity ratio of 0.42. The stock has a market cap of $3.76 billion, a P/E ratio of 19.84, a P/E/G ratio of 2.10 and a beta of 0.89. Amedisys has a 12-month low of $101.61 and a 12-month high of $276.21. The business’s 50 day moving average is $122.52 and its 200-day moving average is $142.33.
In related news, insider David L. Kemmerly sold 2,500 shares of the company’s stock in a transaction on Tuesday, March 29th. The stock was sold at an average price of $177.31, for a total transaction of $443,275.00. Following the completion of the sale, the insider now directly owns 16,336 shares in the company, valued at approximately $2,896,536.16. The sale was disclosed in a filing with the SEC, which is available through this link. Corporate insiders own 2.10% of the company’s stock.
A number of institutional investors have recently bought and sold shares of the business. American Trust bought a new position in Amedisys in the first quarter valued at about $225,000. Vise Technologies Inc. bought a new position in Amedisys in the first quarter valued at about $281,000. Bank of America Corp DE raised its position in Amedisys by 12.5% in the first quarter. Bank of America Corp DE now owns 210,283 shares of the health services provider’s stock valued at $36,229,000 after purchasing an additional 23,445 shares during the last quarter. Neuberger Berman Group LLC raised its position in Amedisys by 13.1% in the first quarter. Neuberger Berman Group LLC now owns 30,143 shares of the health services provider’s stock valued at $5,193,000 after purchasing an additional 3,501 shares during the last quarter. Finally, Capital Research Global Investors raised its position in shares of Amedisys by 8.2% during the first quarter. Capital Research Global Investors now owns 547,066 shares of the health services provider’s stock worth $94,254,000 after acquiring an additional 41,446 shares during the last quarter. Hedge funds and other institutional investors own 90.47% of the company’s stock.
About Amedisys (Get Rating)
Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, Personal Care, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.
- Get a free copy of the StockNews.com research report on Amedisys (AMED)
- Zai Lab Stock Has Fallen to Value Levels
- Are These Cheap Copper Stocks Right For Your Portfolio?
- It’s A Comfortable Time To Buy Steelcase
- Worthington Posts Strong Results, But Earnings Fall On One-Off Adjustments
- A Tasty Entry Point Into Darden Restaurants International
Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.